Search results
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 7 hours agoThe year 2023 marked a significant change in the pharmaceutical industry’s landscape as investment in Covid-19 lost prominence in the aftermath of the...
Cerity Partners LLC Acquires New Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)
ETF DAILY NEWS· 1 day agoCerity Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) during the 4th quarter, according to the company in its most recent disclosure ...
Analyst Report: GSK plc
Morningstar Research via Yahoo Finance· 19 hours agoIn the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including ...
Exclusive: Bernie Sanders worries young people are underestimating the threat from Trump
USA Today· 5 hours agoSen. Bernie Sanders has always been a political maverick, but these days the longest-serving...
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 9 hours agoDiversification of the product portfolio is essential to mitigate this concentration risk....
Pam Cheng
Time Magazine· 2 hours agoIt’s been a challenge to introduce environmentally responsible practices in an industry built on the use of fossil fuels to drive its energy needs, from...
Taro Pharmaceutical Industries (NYSE:TARO) Now Covered by StockNews.com
ETF DAILY NEWS· 4 days agoEquities researchers at StockNews.com began coverage on shares of Taro Pharmaceutical Industries (NYSE:TARO – Get Free Report) in a report issued on Saturday. The firm set a “strong-buy” rating ...
US FDA approves Neurocrine Biosciences' movement disorder drug
Reuters· 3 hours ago, opens new tab Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday. Huntington's disease is an inherited condition that causes the ...
Lyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. via Yahoo Finance· 3 hours agoEarnings per share (EPS) missed analyst estimates by 28%. Looking ahead, revenue is forecast to grow...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
CNBC· 2 days agoThe Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents...
